Coronavirus Live Count Map India
remove_red_eye 1646 Views
1103: Meta-analysis Points to Hydroxychloroquine Benefit Outside Hospitals
- Pooled data meta-analysis from five randomized controlled trials of hydroxychloroquine for the prevention or treatment of COVID-19 noted that early use of the drug by people who were not hospitalized was associated with a statistically significant 24% decrease in risk of infection, hospitalization or death.
- In the individual trials, the drug did not show a statistically significant impact on prevention or treatment.
- The meta-analysis pools together the studies and increases statistical power," mentioned Dr. Joseph Ladapo of the David Geffen School of Medicine at UCLA.
- Infections, hospitalizations and deaths were grouped together into a composite outcome.
- Combining all those events increases the likelihood that researchers will find that treatment had a significant effect.
- Seven nonrandomized controlled trials have demonstrated statistically significant decreased risks with early outpatient use of hydroxychloroquine.
- Along with the meta-analysis, this is extremely robust evidence of benefit.
[SOURCE: https://bit.ly/2SlHEeE medRxiv, online September 30, 2020.]
Dr KK Aggarwal
President CMAAO, HCFI and Past National President IMA